Spinal Cord Stimulation with implantation of Surgical Leads is a sufficient salvage therapy for patients suffering from persistent spinal pain syndrome - a retrospective single-center experience.

PSPS Pain SCS surgical lead

Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 18 07 2024
revised: 27 09 2024
accepted: 28 09 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

Persistent spinal pain syndrome (PSPS) poses a significant medical challenge, often leading to diminished quality of life for affected individuals. In response to this clinical dilemma, Spinal Cord Stimulation (SCS) has emerged as a promising intervention aimed at improving the functional outcomes and overall well-being of patients suffering from these debilitating syndrome. In case a therapy with percutaneous lead fails, e.g. due to a dislocation, surgical lead can be used as a stable alternative. This is resulting in a more invasive procedure and does not allow for intraoperative monitoring. The aim of the study is to investigate the efficacy and safety of the use of surgical leads, as there have been only a few case series published so far. We included PSPS patients that gave consent to a SCS therapy and were treated with Surgical Leads. Outcome scores concerning the quality of life (SF-36), pain related disability (Oswestry disability index [ODI]), sleeping quality (Pittsburgh Sleep Quality Index [PSQI]), and pain intensity (NRS) were obtained prior surgery and at outpatient visits after permanent implantation. In this study, 36 patients were implanted with a Surgical Lead SCS system. One patient developed a new neurological deficit characterized by left-sided leg paresis attributable to postoperative hemorrhage, and another patient experienced a wound infection. These complications contributed to an overall morbidity rate of 5.6%. In overall 5 patients (20.8%) the electrodes were explanted within the first month. Follow-up data of 24 subjects with a median time of 21 [15-47] months were available. The mean pain intensity at rest and in motion was reduced. Further pain depending disability improved from a median ODI SCS with surgical leads is a safe secondary technique to treat PSPS, where treatment with percutaneous leads fail. The results show a promising long-term effect concerning pain intensity and functional outcome.

Identifiants

pubmed: 39395741
pii: S1878-8750(24)01689-9
doi: 10.1016/j.wneu.2024.09.140
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Anton Früh (A)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany; BIH Biomedical Innovation Academy, BIH Charité Junior Digital Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany.

Tarik Alp Sargut (TA)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Melanie Brüßeler (M)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Laura Hallek (L)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Anja Kuckuck (A)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Peter Vajkoczy (P)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Simon Bayerl (S)

Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany; Inter Neuro, Berlin, Germany. Electronic address: simon.bayerl@charite.de.

Classifications MeSH